poisar

Stocks · News reference

8-K filing — CERENOME, INC. (CNSY)

SEC EDGARSEC EDGAR

Filed: 2026-11-16 AccNo: 0001193125-26-462116 Size: 211 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncCerenome, Inc.

    Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress

    Cerenome (Nasdaq: CNSY) reported Q3 2026 results with $0.7M in net diagnostic revenue from its CNSide CSF assay platform. The company expanded payer coverage to ~190M covered lives including new agreements with Aetna, Medical Mutual, and others. REYOBIQ therapeutic program advanced with completed Phase 2 enrollment in recurrent glioblastoma and positive interim Phase 1 multi-dose data in leptomeningeal metastases showing no dose-limiting toxicities. However, the company reported a net loss of $8.7M and cash position of $4.9M as of September 30, 2026.

  2. Globenewswire Inc247Marketnews

    Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO

    Four biotechnology companies presented clinical findings and emerging treatment approaches for brain cancers at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. NeOnc Technologies is preparing for FDA meetings on two programs (NEO100 and NEO212), Cerenome is advancing REYOBIQ therapy and diagnostic tools, Nuvation Bio is expanding data on safusidenib for IDH1-mutant gliomas, and Jazz Pharmaceuticals is progressing dordaviprone through Phase 3 trials for rare brain cancers.